Successful antiretroviral therapy by using unusual antiretroviral combinations in heavily pre-treated patients: two case reports
- 20 October 2014
- journal article
- case report
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 26 (11), 831-834
- https://doi.org/10.1177/0956462414556330
Abstract
In the context of HIV-infected patients with several past antiretroviral therapies and multiple failures, it is possible to be faced with viruses resistant to all drug classes. We report on two HIV-1 infected patients in which the historical genotype showed mutations against all the major drug classes and in which viral suppression has been obtained by non-conventional antiretroviral therapy regimens, including the combination of darunavir at high dosage (800 mg bid), dolutegravir (50 mg bid) and a third agent, i.e. enfuvirtide in the first case and etravirine in the second one.Keywords
This publication has 11 references indexed in Scilit:
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 InfectionNew England Journal of Medicine, 2013
- Clinical Use of HIV Integrase Inhibitors: A Systematic Review and Meta-AnalysisPLOS ONE, 2013
- Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING StudyThe Journal of Infectious Diseases, 2012
- Effects of Etravirine Alone and with Ritonavir-Boosted Protease Inhibitors on the Pharmacokinetics of DolutegravirAntimicrobial Agents and Chemotherapy, 2011
- The Effect of Lopinavir/Ritonavir and Darunavir/Ritonavir on the HIV Integrase Inhibitor S/GSK1349572 in Healthy ParticipantsThe Journal of Clinical Pharmacology, 2011
- Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studiesAIDS, 2010
- Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96Antiviral Therapy, 2009
- Darunavir Inhibitory Quotient Predicts the 48-Week Virological Response to Darunavir-Based Salvage Therapy in Human Immunodeficiency Virus-Infected Protease Inhibitor-Experienced PatientsAntimicrobial Agents and Chemotherapy, 2008
- TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2005
- Structural and Thermodynamic Basis for the Binding of TMC114, a Next-Generation Human Immunodeficiency Virus Type 1 Protease InhibitorJournal of Virology, 2004